159 related articles for article (PubMed ID: 24086588)
1. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.
Lodi S; Phillips A; Fidler S; Hawkins D; Gilson R; McLean K; Fisher M; Post F; Johnson AM; Walker-Nthenda L; Dunn D; Porter K;
PLoS One; 2013; 8(9):e75608. PubMed ID: 24086588
[TBL] [Abstract][Full Text] [Related]
2. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.
Hughes RA; Sterne JA; Walsh J; Bansi L; Gilson R; Orkin C; Hill T; Ainsworth J; Anderson J; Gompels M; Dunn D; Johnson MA; Phillips AN; Pillay D; Leen C; Easterbrook P; Gazzard B; Fisher M; Sabin CA
HIV Med; 2011 Nov; 12(10):583-93. PubMed ID: 21569188
[TBL] [Abstract][Full Text] [Related]
3. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
Ngo-Giang-Huong N; Wittkop L; Judd A; Reiss P; Goetghebuer T; Duiculescu D; Noguera-Julian A; Marczynska M; Giacquinto C; Ene L; Ramos JT; Cellerai C; Klimkait T; Brichard B; Valerius N; Sabin C; Teira R; Obel N; Stephan C; de Wit S; Thorne C; Gibb D; Schwimmer C; Campbell MA; Pillay D; Lallemant M;
BMC Infect Dis; 2016 Nov; 16(1):654. PubMed ID: 27825316
[TBL] [Abstract][Full Text] [Related]
5. Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.
Jose S; Quinn K; Dunn D; Cox A; Sabin C; Fidler S;
HIV Med; 2016 May; 17(5):368-72. PubMed ID: 26306942
[TBL] [Abstract][Full Text] [Related]
6. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
7. Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.
Leung V; Gillis J; Raboud J; Cooper C; Hogg RS; Loutfy MR; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Klein MB;
PLoS One; 2013; 8(10):e77665. PubMed ID: 24204912
[TBL] [Abstract][Full Text] [Related]
8. The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV.
Ahn MY; Jiamsakul A; Khusuwan S; Khol V; Pham TT; Chaiwarith R; Avihingsanon A; Kumarasamy N; Wong WW; Kiertiburanakul S; Pujari S; Nguyen KV; Lee MP; Kamarulzaman A; Zhang F; Ditangco R; Merati TP; Yunihastuti E; Ng OT; Sim BLH; Tanuma J; Ratanasuwan W; Ross J; Choi JY;
J Int AIDS Soc; 2019 Feb; 22(2):e25228. PubMed ID: 30803162
[TBL] [Abstract][Full Text] [Related]
9. Risk of tuberculosis following HIV seroconversion in high-income countries.
Lodi S; del Amo J; d'Arminio Monforte A; Abgrall S; Sabin C; Morrison C; Furrer H; Muga R; Porter K; Girardi E;
Thorax; 2013 Mar; 68(3):207-13. PubMed ID: 23117980
[TBL] [Abstract][Full Text] [Related]
10. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
[TBL] [Abstract][Full Text] [Related]
11. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.
Zugna D; Geskus RB; De Stavola B; Rosinska M; Bartmeyer B; Boufassa F; Chaix ML; Babiker A; Porter K;
Antivir Ther; 2012; 17(6):1039-48. PubMed ID: 22910338
[TBL] [Abstract][Full Text] [Related]
12. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.
Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R;
HIV Med; 2017 Jan; 18(1):33-44. PubMed ID: 27625009
[TBL] [Abstract][Full Text] [Related]
13. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.
Bisson GP; Gross R; Bellamy S; Chittams J; Hislop M; Regensberg L; Frank I; Maartens G; Nachega JB
PLoS Med; 2008 May; 5(5):e109. PubMed ID: 18494555
[TBL] [Abstract][Full Text] [Related]
14. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion.
Stirrup OT; Copas AJ; Phillips AN; Gill MJ; Geskus RB; Touloumi G; Young J; Bucher HC; Babiker AG;
HIV Med; 2018 Mar; 19(3):184-194. PubMed ID: 29230953
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.
Cardoso SW; Luz PM; Velasque L; Torres TS; Tavares IC; Ribeiro SR; Moreira RI; Veloso VG; Moore RD; Grinsztejn B
BMC Infect Dis; 2014 Dec; 14():699. PubMed ID: 25523385
[TBL] [Abstract][Full Text] [Related]
16. Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.
Lima VD; Reuter A; Harrigan PR; Lourenço L; Chau W; Hull M; Mackenzie L; Guillemi S; Hogg RS; Barrios R; Montaner JS
AIDS; 2015 Sep; 29(14):1871-82. PubMed ID: 26165354
[TBL] [Abstract][Full Text] [Related]
17. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China.
Liao L; Xing H; Su B; Wang Z; Ruan Y; Wang X; Liu Z; Lu Y; Yang S; Zhao Q; Vermund SH; Chen RY; Shao Y
AIDS; 2013 Jul; 27(11):1815-24. PubMed ID: 23803794
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.
Rajasuriar R; Gouillou M; Spelman T; Read T; Hoy J; Law M; Cameron PU; Petoumenos K; Lewin SR
PLoS One; 2011; 6(6):e20713. PubMed ID: 21674057
[TBL] [Abstract][Full Text] [Related]
19. European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy.
Guzmán-Fulgencio M; Berenguer J; Micheloud D; Fernández-Rodríguez A; García-Álvarez M; Jiménez-Sousa MA; Bellón JM; Campos Y; Cosín J; Aldámiz-Echevarría T; Catalán P; López JC; Resino S
J Antimicrob Chemother; 2013 Oct; 68(10):2349-57. PubMed ID: 23749950
[TBL] [Abstract][Full Text] [Related]
20. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
